Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain.
Herbert Tejada-MezaÁlvaro Lambea-GilA Sancho SaldañaM Martínez-ZabaletaE Garmendia LopeteguiE López-Cancio MartínezM Castañón ApilánezM Herrera IsasiJ Marta EnguitaB Gómez-VicenteJ F ArenillasN Arenaza BasterrecheaJ J Timiraos FernándezJ Sánchez HerreroJ L Maciñeiras MonteroM Castellanos RodrigoD Fernández-CoudI Casado MenéndezM T Temprano FernándezM FreijoA LunaE J Palacio PortillaY Jiménez LópezE Rodríguez-CastroM Rodríguez-YáñezJ Tejada GarcíaI Beltrán RodríguezF Julián-VillaverdeM P Moreno GarcíaJ M Trejo Gabriel-GalánA Echavarría IñiguezC Pérez LázaroMaría Pilar Navarro-PérezJ Marta Morenonull nullPublished in: European journal of neurology (2020)
A decrease in the number of patients benefiting from reperfusion therapies was found, with a delay in out-of-hospital and door-to-needle times and worse reperfusion rates in northwest Spain. COVID-19 patients had more in-hospital mortality.
Keyphrases
- cerebral ischemia
- acute myocardial infarction
- end stage renal disease
- acute ischemic stroke
- newly diagnosed
- ejection fraction
- chronic kidney disease
- sars cov
- healthcare
- liver failure
- peritoneal dialysis
- prognostic factors
- emergency department
- blood brain barrier
- brain injury
- heart failure
- intensive care unit
- drug induced
- hepatitis b virus
- adverse drug
- atrial fibrillation
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation